NRG-CC009

Open to Accrual

Return to Protocol Table

Protocol Information

Tab containing protocol details, study design, and eligibility criteria
Tab containing study documents, informed consent forms, and study materials
Tab containing information for potential study participants

Phase III Trial of Stereotactic Radiosurgery (SRS) versus Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for Brain Metastases from Small Cell Lung Cancer

Principal Investigator

Vinai Gondi, MD

Status

Open to Accrual

Date Opened To Accrual

January 20, 2021


Disease Site

Symptom Management [CC] Other

Phase

III

Developmental Therapeutics

No

Primary Objective

Determine whether stereotactic radiosurgery (SRS) relative to whole brain radiotherapy with hippocampal avoidance (HA-WBRT) plus memantine for brain metastases from small cell lung cancer (SCLC) prevents cognitive function failure as measured by cognitive decline on a battery of tests: the Hopkins Verbal Learning Test – Revised (HVLT-R), Controled Oral Word Association (COWA) test, and the Trail Making Test (TMT).

Patient Population

Small
cell lung cancer within 5 years of registration

 

Target Accrual

200

Protocol Documents

Available via the National Cancer Institute (NCI) Cancer Trials Support Unit (CTSU) website.


Patient Study Webpage

To learn more about this study, visit the Patient Study Webpage.